Co-Authors
This is a "connection" page, showing publications co-authored by EHAB Y HANNA and SHIRLEY YU SU.
Connection Strength
5.746
-
Outcomes for olfactory neuroblastoma treated with induction chemotherapy. Head Neck. 2017 08; 39(8):1671-1679.
Score: 0.596
-
Esthesioneuroblastoma, neuroendocrine carcinoma, and sinonasal undifferentiated carcinoma: differentiation in diagnosis and treatment. Int Arch Otorhinolaryngol. 2014 Oct; 18(Suppl 2):S149-56.
Score: 0.495
-
Endoscopic resection of sinonasal cancers. Curr Oncol Rep. 2014 Feb; 16(2):369.
Score: 0.473
-
Neurocognitive Functioning of Patients with Sinonasal and Nasopharyngeal Cancers Treated With Multimodality Therapy. J Neurol Surg B Skull Base. 2024 Dec; 85(6):614-621.
Score: 0.231
-
Prevalence of pituitary hormone dysfunction following radiotherapy for sinonasal and nasopharyngeal malignancies. Head Neck. 2023 10; 45(10):2525-2532.
Score: 0.228
-
Impact of Clinical Factors and Treatments on SMARCB1 (INI-1)-Deficient Sinonasal Carcinoma. Otolaryngol Head Neck Surg. 2023 08; 169(2):435-440.
Score: 0.222
-
Functional Outcomes and Quality of Life in Patients with Sinonasal, Nasopharyngeal, and Anterior Skull Base Tumors. Curr Oncol Rep. 2022 06; 24(6):775-781.
Score: 0.207
-
Long-Term Outcomes of Olfactory Neuroblastoma: MD Anderson Cancer Center Experience and Review of the Literature. Laryngoscope. 2022 02; 132(2):290-297.
Score: 0.198
-
Neoadjuvant chemotherapy for locoregionally advanced squamous cell carcinoma of the paranasal sinuses. Cancer. 2021 06 01; 127(11):1788-1795.
Score: 0.192
-
Clinical Implication of Diagnostic and Histopathologic Discrepancies in Sinonasal Malignancies. Laryngoscope. 2021 05; 131(5):E1468-E1475.
Score: 0.187
-
Endoscopic resection of sinonasal malignancies. Head Neck. 2020 04; 42(4):645-652.
Score: 0.178
-
Long-term quality of life after definitive treatment of sinonasal and nasopharyngeal malignancies. Laryngoscope. 2020 01; 130(1):86-93.
Score: 0.167
-
Induction Chemotherapy Response as a Guide for Treatment Optimization in Sinonasal Undifferentiated Carcinoma. J Clin Oncol. 2019 02 20; 37(6):504-512.
Score: 0.166
-
Prognostic factors and survival in adenoid cystic carcinoma of the sinonasal cavity. Head Neck. 2018 12; 40(12):2596-2605.
Score: 0.165
-
Patterns of Treatment Failure in Patients with Sinonasal Mucosal Melanoma. Ann Surg Oncol. 2018 Jun; 25(6):1723-1729.
Score: 0.158
-
Early Stage olfactory neuroblastoma and the impact of resecting dura and olfactory bulb. Laryngoscope. 2018 06; 128(6):1274-1280.
Score: 0.154
-
Approaches to regional lymph node metastasis in patients with head and neck mucosal melanoma. Cancer. 2018 02 01; 124(3):514-520.
Score: 0.153
-
Role of Adjuvant Treatment in Sinonasal Mucosal Melanoma. J Neurol Surg B Skull Base. 2017 Dec; 78(6):512-518.
Score: 0.151
-
Mutation status among patients with sinonasal mucosal melanoma and its impact on survival. Br J Cancer. 2017 Jun 06; 116(12):1564-1571.
Score: 0.148
-
Impact of Previous Surgery and/or Radiation Therapy on Endoscopic Reconstruction Outcomes. Oper Neurosurg (Hagerstown). 2024 Aug 26.
Score: 0.061
-
Orbital and periocular complications in patients with sinonasal tumours with orbital invasion. Br J Ophthalmol. 2024 02 21; 108(3):465-470.
Score: 0.059
-
Does Time to Initiation of Adjuvant Radiotherapy Affect Reconstruction Outcomes after Endoscopic Resection of Skull Base Malignancies? J Neurol Surg B Skull Base. 2024 Oct; 85(5):445-457.
Score: 0.057
-
Predictors of postoperative performance status after surgical management of infratemporal fossa malignancies. Neurosurg Rev. 2023 Jun 29; 46(1):157.
Score: 0.057
-
Patient, Disease, and Treatment-Related Factors Affecting Progression-Free and Disease-Specific Survival in Recurrent Chondrosarcomas of the Skull Base. Oper Neurosurg (Hagerstown). 2023 01 01; 24(1):33-43.
Score: 0.054
-
Neoadjuvant checkpoint inhibitor immunotherapy for resectable mucosal melanoma. Front Oncol. 2022; 12:1001150.
Score: 0.054
-
Soft Tissue Sarcomas of the Head and Neck Region with Skull Base/Intracranial Invasion: Review of Surgical Outcomes and Multimodal Treatment Strategies: A Retrospective Case Series. Curr Oncol. 2022 09 14; 29(9):6540-6550.
Score: 0.054
-
The impact of expanded endoscopic approaches on oncologic and functional outcomes for clival malignancies:a case series. J Neurooncol. 2022 Sep; 159(3):627-635.
Score: 0.053
-
Impact of salvage surgery for recurrent sinonasal cancers with skull base and intracranial involvement. J Neurosurg. 2022 Oct 01; 137(4):961-968.
Score: 0.051
-
The neurosurgical management of sinonasal malignancies involving the anterior skull base: a 28-year experience at The MD Anderson Cancer Center. J Neurosurg. 2022 Jun 01; 136(6):1583-1591.
Score: 0.050
-
The effect of prior radiation on the success of ventral skull base reconstruction: A systematic review and meta-analysis. Head Neck. 2021 09; 43(9):2795-2806.
Score: 0.049
-
Surgical Management of Skull Base Osteoradionecrosis in the Cancer Population - Treatment Outcomes and Predictors of Recurrence: A Case Series. Oper Neurosurg (Hagerstown). 2020 09 15; 19(4):364-374.
Score: 0.047
-
Surgical management of carcinomas of the infratemporal fossa and skull base: patterns of failure and predictors of long-term outcomes. J Neurosurg. 2021 05 01; 134(5):1392-1398.
Score: 0.046
-
Head and neck surgical oncology in the time of a pandemic: Subsite-specific triage guidelines during the COVID-19 pandemic. Head Neck. 2020 06; 42(6):1194-1201.
Score: 0.046
-
Management of olfactory neuroblastoma, neuroendocrine carcinoma, and sinonasal undifferentiated carcinoma involving the skullbase. J Neurooncol. 2020 Dec; 150(3):367-375.
Score: 0.046
-
Patient-reported outcomes, physician-reported toxicities, and treatment outcomes in a modern cohort of patients with sinonasal cancer treated using proton beam therapy. Radiother Oncol. 2020 07; 148:258-266.
Score: 0.046
-
SABR for Skull Base Malignancies: A Systematic Analysis of Set-Up and Positioning Accuracy. Pract Radiat Oncol. 2020 Sep - Oct; 10(5):363-371.
Score: 0.045
-
Surgical Management of Primary Skull Base Osteosarcomas: Impact of Margin Status and Patterns of Relapse. Neurosurgery. 2020 01 01; 86(1):E23-E32.
Score: 0.045
-
A prospective evaluation of health-related quality of life after skull base re-irradiation. Head Neck. 2020 03; 42(3):485-497.
Score: 0.044
-
Patient Outcomes after Reirradiation of Small Skull Base Tumors using Stereotactic Body Radiotherapy, Intensity Modulated Radiotherapy, or Proton Therapy. J Neurol Surg B Skull Base. 2020 Dec; 81(6):638-644.
Score: 0.043
-
Endoscopic endonasal transpterygoid transnasopharyngeal management of petroclival chondrosarcomas without medial extension. J Neurosurg. 2019 07 01; 131(1):184-191.
Score: 0.040
-
Site-Specific Considerations in the Surgical Management of Skull Base Chondrosarcomas. Oper Neurosurg (Hagerstown). 2018 06 01; 14(6):611-619.
Score: 0.040
-
Stereotactic radiosurgery for trigeminal pain secondary to recurrent malignant skull base tumors. J Neurosurg. 2019 03 01; 130(3):812-821.
Score: 0.040
-
Impact of early access to multidisciplinary care on treatment outcomes in patients with skull base chordoma. Acta Neurochir (Wien). 2018 04; 160(4):731-740.
Score: 0.039
-
Cognitive function and patient-reported memory problems after radiotherapy for cancers at the skull base: A cross-sectional survivorship study using the Telephone Interview for Cognitive Status and the MD Anderson Symptom Inventory-Head and Neck Module. Head Neck. 2017 10; 39(10):2048-2056.
Score: 0.038
-
Clinical outcomes after local field conformal reirradiation of patients with retropharyngeal nodal metastasis. Head Neck. 2017 10; 39(10):2079-2087.
Score: 0.038
-
The role of elective nodal irradiation for esthesioneuroblastoma patients with clinically negative neck. Pract Radiat Oncol. 2016 Jul-Aug; 6(4):241-247.
Score: 0.033